Curis, Debiopharm Group Reports Debio 0932 Demonstrated Anti-Tumor Activity

By: via Benzinga
Curis, Inc. (Nasdaq: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.